Journal
ELIFE
Volume 5, Issue -, Pages -Publisher
ELIFE SCIENCES PUBLICATIONS LTD
DOI: 10.7554/eLife.12813
Keywords
-
Categories
Funding
- Schweizerischer Nationalfonds zur Forderung der Wissenschaftlichen Forschung [P2ZHP3_151580]
- Michael J. Fox Foundation for Parkinson's Research [6986]
- Max-Planck-Gesellschaft
- Medical Research Council [MC_UU_12016/3]
- MRC [MC_U127070193, MC_UU_12016/5, G1100713, MC_UP_A500_1020, MC_UU_12016/2] Funding Source: UKRI
- Swiss National Science Foundation (SNF) [P2ZHP3_151580] Funding Source: Swiss National Science Foundation (SNF)
Ask authors/readers for more resources
Mutations in Park8, encoding for the multidomain Leucine-rich repeat kinase 2 (LRRK2) protein, comprise the predominant genetic cause of Parkinson's disease (PD). G2019S, the most common amino acid substitution activates the kinase two- to threefold. This has motivated the development of LRRK2 kinase inhibitors; however, poor consensus on physiological LRRK2 substrates has hampered clinical development of such therapeutics. We employ a combination of phosphoproteomics, genetics, and pharmacology to unambiguously identify a subset of Rab GTPases as key LRRK2 substrates. LRRK2 directly phosphorylates these both in vivo and in vitro on an evolutionary conserved residue in the switch II domain. Pathogenic LRRK2 variants mapping to different functional domains increase phosphorylation of Rabs and this strongly decreases their affinity to regulatory proteins including Rab GDP dissociation inhibitors (GDIs). Our findings uncover a key class of bona-fide LRRK2 substrates and a novel regulatory mechanism of Rabs that connects them to PD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available